CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver
- PMID: 11376565
- PMCID: PMC5926738
- DOI: 10.1111/j.1349-7006.2001.tb01129.x
CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver
Abstract
Combination chemotherapy consisting of 5-fluorouracil (5-FU) and 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxycamptothecin (CPT-11) is a promising regimen for gastrointestinal cancer. The circadian-dependent efficacy and toxicity of 5-FU are related to the circadian variation in the activity of dihydropyrimidine dehydrogenase (DPD), which is a rate-limiting enzyme in the pyrimidine catabolic pathway. To optimize the schedule of the CPT-11 plus 5-FU combination, we investigated the effect of CPT-11 on the circadian rhythm of DPD in vivo. In control mice, the DPD mRNA level in the liver was significantly higher at 14:00 than that at 02:00. After intravenous administration of CPT-11 (30 mg / kg) at 20:00, the circadian rhythm of the DPD mRNA level in the liver was no longer observed 18 h later (14:00), but it was unaffected 6 and 18 h later (at 14:00 and 02:00) when CPT-11 was given at 08:00. In addition, a dose-dependent lengthening of the period of the circadian rhythm of DPD was observed for 42 h after intravenous injection of CPT-11 at 20:00. The levels of DPD protein and activity at 21 h after administration of CPT-11 (at 17:00) were significantly higher than at 9 h (at 05:00). These results suggest that CPT-11 may influence the circadian rhythm of DPD at the transcriptional level. Modulation of the circadian rhythm of DPD by CPT-11 may be a factor in optimizing the combination of 5-FU and CPT-11.
References
-
- Kojima , A. , Shinkai , T. and Saijo , N . Cytogenetic effects of CPT‐11 and its active metabolite, SN‐38 on human lymphocytes . Jpn. J. Clin. Oncol 23 , 116 – 122 ( 1993. ). - PubMed
-
- Conti , J. A. , Kemeny , N. E. , Saltz , L. B. , Huang , Y. , Tong , W. P. , Chou , T. C. , Sun , M. , Pulliam , S. and Gonzalez , C.Irinotecan is an active agent in untreated patients with meta‐static colorectal cancer . J. Clin. Oncol 14 , 709 – 715 ( 1996. ). - PubMed
-
- Vanhoefer , U. , Harstrick , A. , Kohne , C. H. , Achterrath , W. , Rustum , Y. M. , Seeber , S. and Wilke , H . Phase I study of a weekly schedule of irinotecan, high‐dose leucovorin, and infusional fluorouracil as first‐line chemotherapy in patients with advanced colorectal cancer . J. Clin. Oncol , 17 , 907 – 913 ( 1999. ). - PubMed
-
- Ducreux , M. , Ychou , M. , Seitz , J. F. , Bonnay , M. , Bexon , A. , Armand , J. P. , Mahjoubi , M. , Mery‐Mignard , D. and Rougier , P . Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high‐dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose‐finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer . J.Clin. Oncol 17 , 2901 – 2908 ( 1999. ). - PubMed
-
- Saltz , L. B. , Cox , J. V. , Blanke , C. , Rosen , L. S. , Fehrenbacher , L. , Moore , M. J. , Maroun , J. A. , Ackland , S. P. , Locker , P. K. , Pirotta , N. , Elfring , G. L. and Miller , L. L . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group . N. Engl. J. Med 343 , 905 – 914 ( 2000. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases